Features of laboratory indicators in cancer patients with COVID‑19, staying in the intensive care unit

Objective: Comparative analysis of laboratory blood parameters in patients with COVID‑19 without and with oncopathology, who are in the intensive care unit. Materials and methods. A total of 118 people who had had COVID‑19 were examined. The main group consisted of 54 patients with various malignant neoplasms, the control group – 64 patients without oncological pathology. Laboratory parameters of a complete blood count (hemoglobin, leukocytes, lymphocytes, platelets) and a biochemical blood test (total protein, total bilirubin, urea, creatinine, ferritin) were examined. Results. Before COVID‑19 treatment, the average hemoglobin level in patients of the main group was 117.8±5.3 g/l, in the control group – 134.5±1.9 g/l (p=0.008), the average total protein level was 62.0±1.6 g/l and 67.9±0.9 g/l, respectively (p=0.005). After COVID‑19 treatment, hemoglobin in cancer patients remained lower (112.1±5.2 g/l) than in the control group (130.1±1.8 g/l, p=0.004), as well as total protein (60.0±2.0 g/l versus 66.3±0.9 g/l, p=0.004). Also, in patients of the main group after treatment, statistically significantly (p=0.0001) lower levels of lymphocytes (1.3±0.1 cells/ml) were found than in the control group – 2.0±0.1 cells/ml. Conclusion. Cancer patients had reduced levels of hemoglobin, total protein, and lymphocytes before and after treatment for COVID‑19. Increased urea, creatinine, and leukocytes were also noted, which requires enhanced monitoring of their condition.